Antibody Bank
(Kato's Lab; Tohoku University)
Modality
*CasMab (PDPN/ PODXL/ CD44/ EpCAM/ TROP2/ EGFR/ HER2/ HER3/ GPC1)
*mCasMab (mEGFR/ mHER2)
*pCasMab (HER2/ PDPN)
*CART (CD19/ GPC3/ HER2/ PDPN/ PODXL)
*CARM (GPC3)
*Isotype control (mouse/ rat/ human)
*PIT (CD44v/ CD133/ dog/ EpCAM/ PDPN/ PODXL)
*RIT(PDPN/HER2)
mAb list (target)
*CasMab (PDPN/ PODXL/ CD44/ EpCAM/ TROP2/ EGFR/ HER2/ HER3/ GPC1)
*mCasMab (mEGFR/ mHER2)
*pCasMab (HER2/ PDPN)
*CART (CD19/ GPC3/ HER2/ PDPN/ PODXL)
*CARM (GPC3)
*Isotype control (mouse/ rat/ human)
*PIT (CD44v/ CD133/ dog/ EpCAM/ PDPN/ PODXL)
*RIT(PDPN/HER2)
CD: CD10/
CD19/
CD20
(rituximab;
obinutuzumab; ofatumumab)/
CD39/
CD44s
(mG2a/
s+)/
CD73/
CD112R/CD155R(TIGIT)/
CD133/
CD271(NGFR)/
CD273(PD-L2)/
CD274(PD-L1)/
CD276(B7H3)/
CD44v: CD44v3 (mG2a/ v3+)/ CD44v4 (mG2a/ v4+)/ CD44v5 (mG2a/ v5+)/ CD44v6 (mG2a/ v6+/ bivatuzumab)/ CD44v7 (mG2a/ v7+)/ CD44v8 (mG2a/ v8+)/ CD44v9 (mG2a/ v9+)/ CD44v10 (mG2a/ v10+)/
CDH: CDH1 (1+)/ CDH2 (2+)/ CDH3 (3+)/ CDH4 (4+)/ CDH5 (5+)/ CDH6 (6+)/ CDH7 (7+)/ CDH8 (8+)/ CDH9 (9+)/ CDH10 (10+)/ CDH12 (12+)/ CDH13 (13+)/ CDH15 (15+)/ CDH16 (16+)/ CDH17 (17+)/ CDH18 (18+)/ CDH19 (19+)/ CDH20 (20+)/ CDH21 (21+)/ CDH22 (22+)/ CDH23 (23+)/ CDH24 (24+)/ CDH25 (25+)/ CDH26 (26+)/
ChemoR: CCR1 (1+)/ CCR2 (2+)/ CCR3 (3+)/ CCR4 (4+)/ CCR5 (5+)/ CCR6 (6+)/ CCR7 (7+)/ CCR8 (8+)/ CCR9 (9+)/ CCR10 (10+)/ CXCR1 (1+)/ CXCR2 (2+)/ CXCR3 (3+)/ CXCR4 (4+)/ CXCR5 (5+)/ CXCR6 (6+)/ CXCR7 (7+)/ CX3CR1/ XCR1/ ACKR1 (1+)/ ACKR2 (2+)/ ACKR3 (3+)/ ACKR4 (4+; Fab)/ ACKR5 (5+)
EphA/B: EphA1 (A1+)/ EphA2 (mG2a/ A2+)/ EphA3 (A3+)/ EphA4 (mG2a/ A4+)/ EphA5 (mG2a/A5+)/ EphA6 (A6+)/ EphA7 (A7+)/ EphA8 (A8+)/ EphA10 (A10+)/ EphB1 (B1+)/ EphB2 (mG2a/ B2+)/ EphB3/ EphB4 (mG2a/ B4+)/ EphB6 (B6+)/
GPC: GPC1 (mG2a/ 1+)/ GPC2 (2+)/ GPC3 (mG2a/ 3+)/ GPC4 (4+)/ GPC5 (5+)/ GPC6 (6+)/
HER: EGFR (+/cetuximab; panitumumab)/ HER2 (2+/pertuzumab; trastuzumab)/ HER3 (3+/patritumab)/ HER4(4+)/
PDPN: human; mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; T.devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda; rhino; hippo/
Tag: BAPtag/ Histag/ LPtag/ MAPtag/ MBPtag/ PAtag/ RAPtag/ RIEDLtag/
TROP: EpCAM(TROP1)/ TROP2(datopotamab; sacituzumab)/
Virus: Mpox/ SARS-CoV-2 (N/ S2/ bispecific/ bebtelovimab; cilgavimab; casirivimab; bamlanivimab)/
*Others: ATRX/ CA4/ DGK/ GM3/ HGF/ IDH/ KLRG1/ MOTS-c/ PODXL/ RdRP/ SMG1/ TERT/
CD44v: CD44v3 (mG2a/ v3+)/ CD44v4 (mG2a/ v4+)/ CD44v5 (mG2a/ v5+)/ CD44v6 (mG2a/ v6+/ bivatuzumab)/ CD44v7 (mG2a/ v7+)/ CD44v8 (mG2a/ v8+)/ CD44v9 (mG2a/ v9+)/ CD44v10 (mG2a/ v10+)/
CDH: CDH1 (1+)/ CDH2 (2+)/ CDH3 (3+)/ CDH4 (4+)/ CDH5 (5+)/ CDH6 (6+)/ CDH7 (7+)/ CDH8 (8+)/ CDH9 (9+)/ CDH10 (10+)/ CDH12 (12+)/ CDH13 (13+)/ CDH15 (15+)/ CDH16 (16+)/ CDH17 (17+)/ CDH18 (18+)/ CDH19 (19+)/ CDH20 (20+)/ CDH21 (21+)/ CDH22 (22+)/ CDH23 (23+)/ CDH24 (24+)/ CDH25 (25+)/ CDH26 (26+)/
ChemoR: CCR1 (1+)/ CCR2 (2+)/ CCR3 (3+)/ CCR4 (4+)/ CCR5 (5+)/ CCR6 (6+)/ CCR7 (7+)/ CCR8 (8+)/ CCR9 (9+)/ CCR10 (10+)/ CXCR1 (1+)/ CXCR2 (2+)/ CXCR3 (3+)/ CXCR4 (4+)/ CXCR5 (5+)/ CXCR6 (6+)/ CXCR7 (7+)/ CX3CR1/ XCR1/ ACKR1 (1+)/ ACKR2 (2+)/ ACKR3 (3+)/ ACKR4 (4+; Fab)/ ACKR5 (5+)
EphA/B: EphA1 (A1+)/ EphA2 (mG2a/ A2+)/ EphA3 (A3+)/ EphA4 (mG2a/ A4+)/ EphA5 (mG2a/A5+)/ EphA6 (A6+)/ EphA7 (A7+)/ EphA8 (A8+)/ EphA10 (A10+)/ EphB1 (B1+)/ EphB2 (mG2a/ B2+)/ EphB3/ EphB4 (mG2a/ B4+)/ EphB6 (B6+)/
GPC: GPC1 (mG2a/ 1+)/ GPC2 (2+)/ GPC3 (mG2a/ 3+)/ GPC4 (4+)/ GPC5 (5+)/ GPC6 (6+)/
HER: EGFR (+/cetuximab; panitumumab)/ HER2 (2+/pertuzumab; trastuzumab)/ HER3 (3+/patritumab)/ HER4(4+)/
PDPN: human; mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; T.devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda; rhino; hippo/
Tag: BAPtag/ Histag/ LPtag/ MAPtag/ MBPtag/ PAtag/ RAPtag/ RIEDLtag/
TROP: EpCAM(TROP1)/ TROP2(datopotamab; sacituzumab)/
Virus: Mpox/ SARS-CoV-2 (N/ S2/ bispecific/ bebtelovimab; cilgavimab; casirivimab; bamlanivimab)/
*Others: ATRX/ CA4/ DGK/ GM3/ HGF/ IDH/ KLRG1/ MOTS-c/ PODXL/ RdRP/ SMG1/ TERT/
Company (clone)
Abcam
AMab-6/ C44Mab-5/ CMab-43/ EMab-134/ GMab-r1/ H2Mab-139/ HMab-2/ KMab-1/ LpMab-7/ MMab-1/ MsMab-1/ PMab-1/ PcMab-47/ RcMab-1/ SMab-1/ WMab-1
Absolute antibody
PMab-1/ PMab-2/ PMab-292/ PMab-295
APRO (73 mAbs)
AMab-6/ A4Mab-2/ CMab-43/ C1Mab-6/ C2Mab-6/ C2Mab-9/ C3Mab-4/ C4Mab-1/ C5Mab-4/ C6Mab-9/ C6Mab-19/ C7Mab-2/ C8Mab-2/ C9Mab-1/ C9Mab-11/ C9Mab-24/ C39Mab-1/ C39Mab-2/ C20Mab-60/ C44Mab-1/ C44Mab-3/ C44Mab-5/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-94/ C44Mab-108/ C73Mab-9/ CvMab-62/ Cx1Mab-1/ Cx3Mab-4/ Cx4Mab-1/ Cx5Mab-3/ Cx6Mab-1/ Ea1Mab-30/ Ea2Mab-7/ Ea3Mab-20/ Ea4Mab-3/ Ea7Mab-10/ Ea8Mab-9/ Eb2Mab-12/ B4Mab-7/ Eb6Mab-3/ EMab-134/ EMab-300/ G4B1/ HMab-1/ HMab-2/ H2Mab-139/ H2Mab-300/ H2Mab-304/ HisMab-1/ humCvMab-62/ KMab-1/ LpMab-12/ NZ-1/ PMab-1/ PMab-2/ PMab-44/ PMab-231/ PcMab-47/ RdMab-2/ RdMab-13/ RdMab-20/ TmMab-1/ TmMab-2/ TMab-2/ TMab-6/ TpMab-1/ TpMab-3/ TwMab-1/ TrMab-29
BD
C2Mab-6/ C3Mab-4/ C6Mab-9/ C39Mab-2/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-34/ C44Mab-94/ Cx6Mab-1/ CMab-43/ H2Mab-303 (H2Mab-304, H2Mab-307)/ EMab-134/ EMab-300/ LpMab-17/ LpMab-23/ NZ-1/ PMab-1/ RMab-3/ TgMab-2/ TpMab-3
BioLegend
C20Mab-60/ C44Mab-5/ KrMab-3/ LpMab-21/ PMab-1/ PMab-2/ YM-2
CST
C44Mab-3/ C44Mab-9/ C44Mab-108/ KrMab-3/ LpMab-12/ RcMab-1
Exbio
C9Mab-1/ H3Mab-17/ LpMab-23/ PcMab-47/ TrMab-6
FUJIFILM WAKO
AMab-6/ CMab-43/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-46/ C44Mab-94/ C44Mab-108/ EMab-134/ HMab-1/ HMab-2/ MsMab-1/ NZ-1/ NZ-1.2/ PMab-1/ PMab-38/ PcMab-47/ RMab-22/ SMab-1/ TMab-6
Hycult
LpMab-12/ LpMab-13/ LpMab-17
IBL
HMab-1/ SMab-1
MCP
LpMab-3/ LpMab-7/ LpMab-9/ LpMab-12/ LpMab-21
MBL
GMab-r1/ HMab-1/ KMab-1/ KrMab-3/ MMab-1/ MsMab-2/ NZ-1.2/ PMab-1/ RcMab-1/ RMab-3/ SMab-1/ WMab-1
Merck
C8Mab-2/ C44Mab-3/ C44Mab-9/ C44Mab-108/ EpMab-16/ G4B1/ HMab-1/ LpMab-12/ LpMab-13/ LpMab-17/ LpMab-21/ MsMab-1/ NZ-1.2/ PMab-1/ PMab-2/ RMab-3/ RMab-22/ SMab-1/ t8E4/ TpMab-3/ TrMab-29/ TwMab-1
Novus
NZ-1.2/ PMab-1
Zenogen
LpMab-7/ LpMab-12/ PMab-38/ PMab-44/ PMab-48/ PMab-52/ PMab-202/ PMab-210/ PMab-213/ PMab-219/ PMab-225/ PMab-231/ PMab-233/ PMab-235/ PMab-237/ PMab-247/ PMab-256/ NZ-1.2
Back to list
AMab-6/ C44Mab-5/ CMab-43/ EMab-134/ GMab-r1/ H2Mab-139/ HMab-2/ KMab-1/ LpMab-7/ MMab-1/ MsMab-1/ PMab-1/ PcMab-47/ RcMab-1/ SMab-1/ WMab-1
Absolute antibody
PMab-1/ PMab-2/ PMab-292/ PMab-295
APRO (73 mAbs)
AMab-6/ A4Mab-2/ CMab-43/ C1Mab-6/ C2Mab-6/ C2Mab-9/ C3Mab-4/ C4Mab-1/ C5Mab-4/ C6Mab-9/ C6Mab-19/ C7Mab-2/ C8Mab-2/ C9Mab-1/ C9Mab-11/ C9Mab-24/ C39Mab-1/ C39Mab-2/ C20Mab-60/ C44Mab-1/ C44Mab-3/ C44Mab-5/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-94/ C44Mab-108/ C73Mab-9/ CvMab-62/ Cx1Mab-1/ Cx3Mab-4/ Cx4Mab-1/ Cx5Mab-3/ Cx6Mab-1/ Ea1Mab-30/ Ea2Mab-7/ Ea3Mab-20/ Ea4Mab-3/ Ea7Mab-10/ Ea8Mab-9/ Eb2Mab-12/ B4Mab-7/ Eb6Mab-3/ EMab-134/ EMab-300/ G4B1/ HMab-1/ HMab-2/ H2Mab-139/ H2Mab-300/ H2Mab-304/ HisMab-1/ humCvMab-62/ KMab-1/ LpMab-12/ NZ-1/ PMab-1/ PMab-2/ PMab-44/ PMab-231/ PcMab-47/ RdMab-2/ RdMab-13/ RdMab-20/ TmMab-1/ TmMab-2/ TMab-2/ TMab-6/ TpMab-1/ TpMab-3/ TwMab-1/ TrMab-29
BD
C2Mab-6/ C3Mab-4/ C6Mab-9/ C39Mab-2/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-34/ C44Mab-94/ Cx6Mab-1/ CMab-43/ H2Mab-303 (H2Mab-304, H2Mab-307)/ EMab-134/ EMab-300/ LpMab-17/ LpMab-23/ NZ-1/ PMab-1/ RMab-3/ TgMab-2/ TpMab-3
BioLegend
C20Mab-60/ C44Mab-5/ KrMab-3/ LpMab-21/ PMab-1/ PMab-2/ YM-2
CST
C44Mab-3/ C44Mab-9/ C44Mab-108/ KrMab-3/ LpMab-12/ RcMab-1
Exbio
C9Mab-1/ H3Mab-17/ LpMab-23/ PcMab-47/ TrMab-6
FUJIFILM WAKO
AMab-6/ CMab-43/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-46/ C44Mab-94/ C44Mab-108/ EMab-134/ HMab-1/ HMab-2/ MsMab-1/ NZ-1/ NZ-1.2/ PMab-1/ PMab-38/ PcMab-47/ RMab-22/ SMab-1/ TMab-6
Hycult
LpMab-12/ LpMab-13/ LpMab-17
IBL
HMab-1/ SMab-1
MCP
LpMab-3/ LpMab-7/ LpMab-9/ LpMab-12/ LpMab-21
MBL
GMab-r1/ HMab-1/ KMab-1/ KrMab-3/ MMab-1/ MsMab-2/ NZ-1.2/ PMab-1/ RcMab-1/ RMab-3/ SMab-1/ WMab-1
Merck
C8Mab-2/ C44Mab-3/ C44Mab-9/ C44Mab-108/ EpMab-16/ G4B1/ HMab-1/ LpMab-12/ LpMab-13/ LpMab-17/ LpMab-21/ MsMab-1/ NZ-1.2/ PMab-1/ PMab-2/ RMab-3/ RMab-22/ SMab-1/ t8E4/ TpMab-3/ TrMab-29/ TwMab-1
Novus
NZ-1.2/ PMab-1
Zenogen
LpMab-7/ LpMab-12/ PMab-38/ PMab-44/ PMab-48/ PMab-52/ PMab-202/ PMab-210/ PMab-213/ PMab-219/ PMab-225/ PMab-231/ PMab-233/ PMab-235/ PMab-237/ PMab-247/ PMab-256/ NZ-1.2
anti-dog protein monoclonal antibodies
| dog PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (134-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
done | |
| anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
| dog HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
| anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
| EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 | FACS, IHC | done | ||
| anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
| anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done | |
| anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |
anti-cat protein monoclonal antibodies
| cat MET | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-cat MET mAb (cMMab-1; mouse IgG1, kappa) |
specific for cat MET (No. 43) | FACS | done | ||
| anti-cat MET mAb (cMMab-2; mouse IgG1, kappa) |
specific for cat MET (No. 46) | FACS | done | ||
| anti-cat MET mAb (cMMab-3; mouse IgG1, kappa) |
specific for cat MET (No. 62) | FACS | done | ||
| anti-cat MET mAb (cMMab-4; mouse IgG1, kappa) |
specific for cat MET (No. 63) | FACS | done | ||
| anti-cat MET mAb (cMMab-5; mouse IgG1, kappa) |
specific for cat MET (No. 102) | FACS | done | ||
| anti-cat MET mAb (cMMab-6; mouse IgG1, kappa) |
specific for cat MET (No. 106) | FACS | done | ||
| anti-cat MET mAb (cMMab-7; mouse IgG1, kappa) |
specific for cat MET (No. 115) | FACS | done | ||
| anti-cat MET mAb (cMMab-8; mouse IgG1, kappa) |
specific for cat MET (No. 116) | FACS | done | ||
| anti-cat MET mAb (cMMab-9; mouse IgG1, kappa) |
specific for cat MET (No. 126) | FACS | done | ||
| anti-cat MET mAb (cMMab-10; mouse IgG1, kappa) |
specific for cat MET (No. 173) | FACS | done | ||
| anti-cat MET mAb (cMMab-11; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-12; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-13; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-14; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-15; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-16; mouse IgG2a, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-17; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-18; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-19; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-20; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-21; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-22; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-23; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-24; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-25; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-26; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-27; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-28; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-29; mouse IgG2a, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-30; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-31; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-32; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-33; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-34; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (cMMab-35; mouse IgG2a, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-36; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-37; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-38; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-39; mouse Ig) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-40; mouse Ig) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-41; mouse Ig) |
specific for cat MET | FACS | |||
| cat MET mouse-cat chimera | Character | Application | Ref | Gene cloning | Company |
| anti-cat MET mAb (chcMMab-13; cat IgG, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| anti-cat MET mAb (chcMMab-25; cat IgG, kappa) |
specific for cat MET | FACS, agonistic | done | ||
| cat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
| anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
crossreact with cat PDPN | IHC, WB, FACS | PMab-231 epitope; lion |
done |
APRO zenogen |
| anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) |
defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
CasMab
| PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab; patent |
IHC, WB, FACS | PDPN_review LpMab-2 |
done | restricted |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | IHC, WB, FACS |
LpMab-23 IHC patent |
done | restricted | |
| anti-hPDPN mAb (PMab-117; rat IgM, kappa) | FACS |
humPMab-117 PMab-117-mG2a Cells2022 |
done | restricted | |
| PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-human PDPN mAb(chLpMab-2; human IgG1, kappa) |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP, IHC, WB, FACS | chLpMab-2 | done | restricted |
| anti-human PDPN mAb(humLpMab-2; human IgG1, kappa) |
CasMab for human PDPN; humanized mAb originated from LpMab-2 | FACS | done | restricted | |
| anti-human PDPN mAb (chLpMab-23; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | chLpMab-23 | done | restricted |
| anti-human PDPN mAb (humLpMab-23-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from LpMab-23 | IHC, WB, FACS | humLpMab-23-f | done | restricted |
| anti-human PDPN mAb (PMab-117-mG2a-f; mouse IgG2a) | CasMab for human PDPN; mouse IgG2a version of PMab-117 | FACS | PMab-117-mG2a | done | restricted |
| anti-human PDPN mAb (chPMab-117; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from PMab-117 | FACS | done | restricted | |
| anti-human PDPN mAb (humPMab-117-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from PMab-117 | FACS | humPMab-117 | done | restricted |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab
|
FACS | PcMab-6 patent |
done | restricted |
| anti-PODXL mAb (PcMab-60; mouse IgM, kappa) |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
done | restricted |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
| anti-PODXL mAb (PcMab-6-mG2a-f; mouse IgG2a) |
anti-PODXL CasMab; IgG2a version of PcMab-6
|
FACS, ADCC/CDC | PcMab-6-mG2a-f | done | restricted |
| anti-PODXL mAb (PcMab-6-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-6 | FACS, ADCC/CDC | done | restricted | |
| anti-PODXL mAb (humPcMab-6-f; human IgG1) |
CasMab for PODXL; humanized mAb originated from PcMab-6 |
FACS | humPcMab-6-f | done | restricted |
| anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | done | restricted |
| anti-PODXL mAb (60-mG2a-f; mouse IgG2a, kappa) |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | done | restricted |
| anti-PODXL mAb (PcMab-60-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-60 | FACS, ADCC/CDC | done | restricted | |
| anti-PODXL mAb (humPcMab-60; human IgG1) |
anti-PODXL CasMab; humanized PcMab-60
|
FACS, ADCC/CDC | humPcMab-60 | done | restricted |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-1012; mouse IgM, kappa) |
Mab1 for CD44s (exon-7) cossreact with mouse CD44 |
FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1075; mouse IgG2a, kappa) |
Mab2 for CD44s (exon-7) | FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1095; mouse IgG1, kappa) |
Mab3 for CD44s (exon-7) | FACS | done | restricted | |
| CD44s | Character | Application | Ref | Gene cloning | Company |
| anti-CD44s mAb (C44Mab-1012-mG1; mouse IgG1) |
Mab1 for CD44s (exon-7) | FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1012-hG1; human IgG1) |
Mab1 for CD44s (exon-7) | FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1075-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1095-mG2a; mouse IgG2a, kappa) | mouse IgG2a type | FACS | done | restricted | |
| anti-CD44s mAb (C44Mab-1095-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa) |
Mab6 for CD44v3 | FACS, WB, IHC | done | restricted | |
| anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa) |
Mab11 for CD44v3 | FACS, WB, IHC | done | restricted | |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v3 mAb (C44Mab-1080-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | done | restricted | |
| anti-CD44v3 mAb (C44Mab-1006-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | ongoing | restricted | |
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa) |
Mab8 for CD44v5 | FACS, WB, IHC | done | restricted | |
| anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa) |
Mab12 for CD44v5 | FACS, WB, IHC | done | restricted | |
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-1088-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | done | restricted | |
| anti-CD44v5 mAb (C44Mab-1003-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | ongoing | restricted | |
| CD44v6 original | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa) |
V6-1 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa) |
V6-2 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
V6-3 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa) |
V6-4 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa) |
V6-5 (IgG3) for CD44v6 | FACS, WB, IHC | done | restricted | |
| CD44v6 mouse IgG1 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074-mG1; mouse IgG1, kappa) |
V6-1 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1089-mG1; mouse IgG1, kappa) |
V6-4 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1092-mG1; mouse IgG1, kappa) |
V6-5 for CD44v6 | FACS, WB, IHC | done | restricted | |
| CD44v6 human IgG1 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074-hG1; human IgG1, kappa) |
V6-1 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1079-hG1; human IgG1, kappa) |
V6-2 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1081-hG1; human IgG1, kappa) |
V6-3 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1089-hG1; human IgG1, kappa) |
V6-4 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1092-hG1; human IgG1, kappa) |
V6-5 for CD44v6 | FACS, WB, IHC | done | restricted | |
| CD44v6 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa) |
scFv from V6-1 | CAR-T or TCE | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa) |
scFv from V6-2 | CAR-T or TCE | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
scFv from V6-3 | CAR-T or TCE | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa) |
scFv from V6-4 | CAR-T or TCE | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa) |
scFv from V6-5 | CAR-T or TCE | done | restricted | |
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa) |
Mab4 for CD44v7 | FACS, WB, IHC | done | restricted | |
| anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa) |
Mab5 for CD44v7 | FACS, WB, IHC | done | restricted | |
| anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa) |
Mab10 for CD44v7 | FACS, WB, IHC | done | restricted | |
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7 mAb (C44Mab-1030-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1048-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1034-hG1; human IgG1, kappa) |
human IgG1 type | FACS, WB, IHC | ongoing |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-1123; mouse IgM, kappa) |
Mab1 for EpCAM | FACS | ongoing | restricted | |
| anti-EpCAM mAb (EpMab-1138; mouse IgM, kappa) |
Mab2 for EpCAM | FACS | ongoing | restricted | |
| anti-EpCAM mAb (EpMab-1147; mouse IgG1, kappa) |
Mab3 for EpCAM | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1007; mouse IgG1, kappa) |
Mab4 for EpCAM | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1013; mouse IgG1, kappa) |
Mab5 for EpCAM | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1022; mouse IgG1, kappa) |
Mab6 for EpCAM | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1069; mouse IgG1, kappa) |
Mab7 for EpCAM | FACS | done | restricted | |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
| anti-EpCAM mAb (EpMab-1147-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1007-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1013-hG1; human IgG1 IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1022-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1069-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
| anti-EpCAM mAb (EpMab-1147-mG2a; mouse IgG2a, kappa) |
mouse IgG2a type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1007-mG2a; mouse IgG2a, kappa) |
mouse IgG2a type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1013-mG2a; mouse IgG2a, kappa) |
mouse IgG2a type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1022-mG2a; mouse IgG2a, kappa) |
mouse IgG2a type | FACS | done | restricted | |
| anti-EpCAM mAb (EpMab-1069-mG2a; mouse IgG2a, kappa) |
mouse IgG2a type | FACS | done | restricted |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb (TrMab-1100; mouse IgG1, kappa) |
Mab1 for human TROP2 | FACS | done | restricted | |
| anti-TROP2 mAb (TrMab-1148; mouse IgG1, kappa) |
Mab3 for human TROP2 | FACS | done | restricted | |
| anti-TROP2 mAb (TrMab-1156; mouse IgG2b, kappa) |
Mab4 for human TROP2 | FACS | done | restricted | |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
| anti-TROP2 mAb (TrMab-1100-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-TROP2 mAb (TrMab-1148-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted | |
| anti-TROP2 mAb (TrMab-1156-hG1; human IgG1, kappa) |
human IgG1 type | FACS | done | restricted |
| EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb (ECasMab-1001; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1002; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1003; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1004; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1005; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1006; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1007; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1008; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1009; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1010; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1011; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1012; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1013; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1014; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1015; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1016; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1017; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1018; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1019; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1020; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted | |
| EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (ECasMab-1001-hG1; human IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1009-hG1; human IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1016-hG1; human IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1020-hG1; human IgG1, kappa) |
specific for EGFR | FACS | done | restricted |
| HER2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2CasMab-1; mouse IgG1,kappa) |
H2Mab-214; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-214 | done | restricted |
| anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (H2Mab-1245; mouse IgG1,kappa) |
Mab-34; domain-I; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1268; mouse IgG1,kappa) |
Mab-35; domain-I; specific for HER2 or endogenous dog HER2 | FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1278; mouse IgG1,kappa) |
Mab-38; domain-I; specific for HER2 or endogenous dog HER2 | FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1180; mouse IgG1, kappa) |
Mab-33; domain-III; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1190; mouse IgG1,kappa) |
Mab-36; domain-III; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1262; mouse IgG1,kappa) |
Mab-37; domain-III; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | restricted | |
| HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-250-mG2af; mouse IgG2a,kappa) |
H2CasMab-2; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (H2Mab-250-hG1-f; human IgG1,kappa) |
H2CasMab-2; specific for HER2; domain-IV | ADCC/CDC; antitumor activities | 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (humH2Mab-250-f; human IgG1,kappa) |
humanized H2Mab-250; H2CasMab-2; specific for HER2; domain-IV |
ADCC/CDC; antitumor activities | done | restricted | |
| anti-HER2 mAb (H2Mab-214-mG2af; mouse IgG2a,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | 214-mG2a-f | done | restricted |
| anti-HER2 mAb (H2Mab-214-hG1; human IgG1,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | done | restricted |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb (H3Mab-1059; mouse IgG1,kappa) |
Mab1 for HER3 | FACS | done | restricted | |
| anti HER3 mAb (H3Mab-1170; mouse IgG1,kappa) |
Mab2 for HER3 | FACS | done | restricted | |
| HER3 | Character | Application | Ref | Gene cloning | Company |
| anti HER3 mAb (H3Mab-1059-mG2a; mouse IgG2a,kappa) |
mouse IgG2a type | FACS | done | restricted | |
| anti HER3 mAb (H3Mab-1170-mG2a; mouse IgG2a,kappa) |
mouse IgG2a type | FACS | done | restricted | |
| HER3 | Character | Application | Ref | Gene cloning | Company |
| anti HER3 mAb (H3Mab-1059-hG1; human IgG1,kappa) |
human IgG1 type | FACS | done | restricted | |
| anti HER3 mAb (H3Mab-1170-hG1; human IgG1,kappa) |
human IgG1 type | FACS | done | restricted |
| GPC1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti GPC1 mAb (G1Mab-1013; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1014; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1072; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1080; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1085; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1091; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted | |
| anti GPC1 mAb (G1Mab-1095; mouse IgG1,kappa) |
specific for GPC1 | FACS | ongoing | restricted |
mCasMab
| mouse EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb (EMab-1302; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | done | restricted | |
| anti-EGFR mAb (EMab-1303; rat IgM, kappa) | crossreact with human EGFR; domain-III
candidate |
FACS | done | restricted | |
| anti-EGFR mAb (EMab-1304; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | done | restricted | |
| mouse EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-1303-mG1; mouse IgG1, kappa) | mouse IgG1 type of EMab-1303 | FACS | done | restricted | |
| anti-EGFR mAb (EMab-1303-mG2a; mouse IgG2a, kappa) | mouse IgG2a type of EMab-1303 | FACS | done | restricted | |
| anti-EGFR mAb (EMab-1303-hG1; human IgG1, kappa) | humna IgG1 type of EMab-1303 | FACS | done | restricted | |
| anti-EGFR mAb (EMab-1303-scFv) | scFv of EMab-1303 | FACS | done | restricted |
| mouse HER2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2Mab-1301; rat IgG2a, lambda) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1316; rat IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1319; rat IgG2a, lambda) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | restricted | |
| mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1,lambda) |
hIgG1 version of H2Mab-1301;
cross-react with HER2 (human) |
FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1316; cross-react with HER2 (human) |
FACS | done | restricted | |
| anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1,lambda) |
hIgG1 version of H2Mab-1319; cross-react with HER2 (human) |
FACS | done | restricted |
pCasMab
| HER2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2CasMab-3; mouse IgG3,kappa) |
mAb-279; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-4; mouse IgG1,kappa) |
mAb-280; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-5; mouse IgG1,kappa) |
mAb-281; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-6; mouse IgG2a,kappa) |
mAb-282; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-7; mouse IgG1,kappa) |
mAb-283; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-8; mouse IgG1,kappa) |
mAb-284; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-9; mouse IgG3,kappa) |
mAb-285; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-10; mouse IgG1,kappa) |
mAb-286; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-11; mouse IgG1,kappa) |
mAb-287; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-12; mouse IgG1,kappa) |
mAb-288; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-13; mouse IgG1,kappa) |
mAb-289; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-14; mouse IgG1,kappa) |
mAb-290; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-15; mouse IgG3,kappa) |
mAb-291; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-16; mouse IgG3,kappa) |
mAb-292; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-17; mouse IgG3,kappa) |
mAb-293; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-18; mouse IgG1,kappa) |
mAb-294; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-19; mouse IgG1,kappa) |
mAb-295; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-20; mouse IgG1,kappa) |
mAb-296; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-21; mouse IgG2a,kappa) |
mAb-297; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-22; mouse IgG1,kappa) |
mAb-298; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-23; mouse IgG1,kappa) |
mAb-299; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted |
| PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (P85Mab-1; mouse IgG1,kappa) |
specific for PDPN | FACS, IHC | done | restricted |
CAR-T
| CD19 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb (C19Mab-2; mouse IgG1,kappa) | specific for CD19; CBIS method; LN229/CD19 immunization | FACS | done | CD19 humanized | Character | Application | Ref | Gene cloning | Company |
| anti-CD19 mAb (humC19Mab-2; human IgG1,kappa) | specific for CD19 | FACS | done | CD19 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-CD19 mAb (humC19Mab-2 -scFv) |
scFv of humanized C19Mab-2 | FACS | done | iPS |
| GPC3 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC3 mAb (G3Mab-1; mouse IgG1, kappa) |
specific for human GPC3 ref: abcam |
FACS | done | ||
| anti-GPC3 mAb (G3Mab-2; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (G3Mab-3; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| GPC3 humanized | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-1; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-2; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-3; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| GPC3 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-1-scFv-Fc) |
specific for human GPC3 | CAR-T | done | ||
| anti-GPC3 mAb (humG3Mab-2-scFv-Fc) |
specific for human GPC3 | CAR-T | done | iPS | |
| anti-GPC3 mAb (humG3Mab-3-scFv-Fc) |
specific for human GPC3 | CAR-T | done | iPS |
| HER2 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| HER2 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2CasMab-2-scFv-Fc) |
specific for HER2; domain-IV |
CART | Cell Stem Cell | done | restricted |
| PDPN original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (NZ-1; rat IgG2a, lambda) |
specific for human PDPN | IP, IHC, WB, FACS (Review) |
NZ-1 | done |
APRO |
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | restricted |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab
|
IHC, WB, FACS |
LpMab-23 IHC patent |
done | restricted |
| anti-hPDPN mAb (PMab-117; rat IgM, kappa) | CasMab | FACS |
humPMab-117 PMab-117-mG2a Cells2022 |
done | restricted |
| PDPN humanized | Character | Application | Ref | Gene cloning | Company |
| anti-human PDPN mAb (NZ-27; human IgG1, lambda) | specific for human PDPN; humanized mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-27 | done | |
| anti-hPDPN mAb (humLpMab-23; human IgG1, kappa) |
|
IHC, WB, FACS | humLpMab-23-f | done | restricted |
| anti-hPDPN mAb (humPMab-117; human IgG1, kappa) | FACS | humPMab-117 | done | restricted | |
| PDPN scFv | Character | Application | Ref | Gene cloning | Company |
| anti-human PDPN mAb (NZ-1-scFv-Fc) |
scFv originated from NZ-1 | CART | CAR-T | done | |
| anti-human PDPN mAb (NZ-27-scFv-Fc) |
scFv originated from NZ-27 | CART | CAR-T | done | |
| anti-human PDPN mAb (LpMab-2-scFv-Fc) |
CasMab for human PDPN; scFv originated from LpMab-2 |
CART | CAR-T | done | restricted |
| anti-hPDPN mAb (humLpMab-23-scFv-Fc) | CasMab for human PDPN; scFv originated from LpMab-23 |
CART | done | restricted | |
| anti-hPDPN mAb (humPMab-117-scFv-Fc) |
CasMab for human PDPN; scFv originated from PMab-117 |
CART | done | restricted |
| Podocalyxin original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | PcMab-6 patent |
done | restricted |
| Podocalyxin humanized | Character | Application | Ref | Gene cloning | Company |
| anti-PODXL mAb (humPcMab-6; human IgG1, kappa) |
anti-PODXL CasMab | FACS | humPcMab-6-f | done | restricted |
| Podocalyxin scFv | Character | Application | Ref | Gene cloning | Company |
| anti-hPDPN mAb (humPcMab-6-scFv; scFv) | CasMab; scFv originated from PcMab-6 |
CART | CAR-T | done | restricted |
CAR-M
| GPC3 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC3 mAb (G3Mab-4; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| GPC3 converted | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (G3Mab-4-mG1; mouse IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (G3Mab-4-mG2a; mouse IgG2a, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| GPC3 humanized | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-4; human IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| GPC3 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-4-scFv-mG2a) |
specific for human GPC3 | FACS, WB | done | UI |
RIT
| PDPN for RIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-human PDPN mAb (NZ-1; rat IgG2a, lambda) |
specific for human PDPN | IP, IHC, WB, FACS | RIT | done | Duke |
| anti-human PDPN mAb (NZ-12; human IgG1, lambda) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | RIT | done | QST |
| anti-human PDPN mAb (NZ-16; human IgG1, lambda) | specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | RIT | done | QST |
| HER2 for RIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-HER2 mAb (RIT-1; mouse IgG1, kappa) |
H139-like; domain-I; specific for HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (RIT-2; mouse IgG1, kappa) |
H193-like; domain-II; specific for HER2 | FACS | done | ||
| anti-HER2 mAb (RIT-3; mouse IgG1, kappa) |
H181-like; domain-III; specific for HER2 | FACS, IHC, WB | done | ||
| anti-HER2 mAb (RIT-4; mouse IgG2b, kappa) |
H41-like; domain-IV; specific for HER2 | FACS | done | ||
| HER2 chimera | Character | Application | Ref | Gene cloning | Collaboration |
| anti-HER2 mAb (RIT-1; human IgG1, kappa) |
H139-like; domain-I; specific for HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (RIT-2; human IgG1, kappa) |
H193-like; domain-II; specific for HER2 | FACS | done | ||
| anti-HER2 mAb (RIT-3; human IgG1, kappa) |
H181-like; domain-III; specific for HER2 | FACS, IHC, WB | done | ||
| anti-HER2 mAb (RIT-4; human IgG1, kappa) |
H41-like; domain-IV; specific for HER2 | FACS | done | ||
| HER2 humanized | Character | Application | Ref | Gene cloning | Collaboration |
| anti-HER2 mAb (humRIT-1; human IgG1, kappa) |
hum_H139-like; specific for HER2 domain-I | FACS | done | ||
| anti-HER2 mAb (humRIT-2; human IgG1, kappa) |
hum_H193-like; specific for HER2 domain-II | FACS | x | ||
| anti-HER2 mAb (humRIT-3; human IgG1, kappa) |
hum_H181-like; specific for HER2 domain-III | FACS | done | ||
| anti-HER2 mAb (humRIT-4; human IgG1, kappa) |
hum_H41-like; specific for HER2 domain-IV | FACS | done | ||
| HER2 scFv | Character | Application | Ref | Gene cloning | Collaboration |
| anti-HER2 mAb (humRIT-1-scFv-Fc) |
scFv from humRIT-1 | FACS | |||
| anti-HER2 mAb (humRIT-2-scFv-Fc) |
scFv from humRIT-2 | FACS | |||
| anti-HER2 mAb (humRIT-3-scFv-Fc) |
scFv from humRIT-3 | FACS | |||
| anti-HER2 mAb (humRIT-4-scFv-Fc) |
scFv from humRIT-4 | FACS |
PIT
| PDPN for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-human PDPN mAb (NZ-1; rat IgG2a, lambda) |
specific for human PDPN | IP, IHC, WB, FACS | Nagoya; Rowan | done | Nagoya, NIH, Rowan |
| anti-human PDPN mAb (NZ-1-Fab; rat IgG2a, lambda) |
Fab of NZ-1 | IP, IHC, WB, FACS | done | Rowan | |
| anti-human PDPN mAb (NZ-27; human IgG1, lambda) | humanized mAb originated from NZ-1 | IP, IHC, WB, FACS | done | Rowan | |
| anti-human PDPN mAb (LpMab-3; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-7; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-9; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-10; mouse IgG3, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-12; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-13; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-16; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-17; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-19; mouse IgG2b, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH | |
| anti-human PDPN mAb (LpMab-21; mouse IgG2a, kappa) | specific for human PDPN | IHC, WB, FACS | done | NIH |
| PODXL for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-47; mouse IgG1, kappa) |
specific for human PODXL | FACS, WB, IHC | done | NIH | |
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | done | NIH | |
| anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | done | NIH |
| EpCAM for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-37; mouse IgG1, kappa) |
specific for EpCAM | FACS, WB, IHC | done | KMU |
| CD44v for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa) |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa) |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | done | NIH | |
| anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa) |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa) |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa) |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa) |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa) |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | done | NIH | |
| anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa) |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | done | NIH |
| CD133 for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-CD133 mAb (CMab-43; mouse IgG2a, kappa) |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities |
done | NIH | |
| anti-CD133 mAb (CMab-44; mouse IgG1, kappa) |
specific for CD133; detects AML |
FACS, WB | done | NIH |
| dog antigen for PIT | Character | Application | Ref | Gene cloning | Collaboration |
|---|---|---|---|---|---|
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
specific for dog PDPN | IHC, WB, FACS | done | NIH | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | done | NIH | |
| anti-dog EGFR mAb (E134Bf; dog IgGB, kappa) |
specific for dog EGFR | IHC, WB, FACS | done | NIH | |
| anti-dog PDPN mAb (H77Bf; dog IgGB, kappa) |
specific for dog HER2 | IHC, WB, FACS | done | NIH | |
| anti-dog PDPN mAb (H2Mab-41; dog IgGB, kappa) |
specific for dog HER2 | FACS | done | NIH |